Drug: ABREVA Injury: Application site vesicles Quarter: 2016Q3
Total Records: 6 Number of Pages: 1
Event ID | DRUGNAME | PT | Drug Manufacturer | Patient Age | Sex | Weight | Date (YYYYMMDD) | Country |
---|---|---|---|---|---|---|---|---|
125401171 | ABREVA | Application site vesicles | GLAXOSMITHKLINE | 64.00 YR | F | 0 | 20160708 | US |
125571771 | ABREVA | Application site vesicles | GLAXOSMITHKLINE | 48.00 YR | F | 0 | 20160714 | US |
126223131 | ABREVA | Application site vesicles | GLAXOSMITHKLINE | 31.00 YR | F | 0 | 20160804 | US |
127662861 | ABREVA | Application site vesicles | GLAXOSMITHKLINE | 66.00 YR | F | 0 | 20160921 | US |
127709331 | ABREVA | Application site vesicles | GLAXOSMITHKLINE | 0.00 | 0 | 20160922 | US | |
127953681 | ABREVA | Application site vesicles | GLAXOSMITHKLINE | 49.00 YR | F | 0 | 20160929 | US |
Total Records: 6 Number of Pages: 1